Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Immunocore Holdings plc ADR (NASDAQ: IMCR) was $36.07 for the day, down -3.17% from the previous closing price of $37.25. In other words, the price has decreased by -$3.17 from its previous closing price. On the day, 0.78 million shares were traded. IMCR stock price reached its highest trading level at $37.461 during the session, while it also had its lowest trading level at $35.38.
Ratios:
Our analysis of IMCR’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 69.48. For the most recent quarter (mrq), Quick Ratio is recorded 6.31 and its Current Ratio is at 6.36. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on May 27, 2025, initiated with a Buy rating and assigned the stock a target price of $65.
On December 13, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $74 to $35.
Mizuho Downgraded its Outperform to Neutral on November 11, 2024, whereas the target price for the stock was revised from $72 to $38.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 17 ’25 when BAKER BROS. ADVISORS LP bought 807,338 shares for $29.72 per share. The transaction valued at 23,993,224 led to the insider holds 2,144,060 shares of the business.
Brian Di Donato bought 100,000 shares of IMCR for $3,000,000 on Mar 17 ’25. On Mar 14 ’25, another insider, Brian Di Donato, who serves as the affiliate of the company, bought 56,250 shares for $29.13 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMCR now has a Market Capitalization of 1871203328 and an Enterprise Value of 1408891264. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.42 while its Price-to-Book (P/B) ratio in mrq is 4.81. Its current Enterprise Value per Revenue stands at 4.224 whereas that against EBITDA is -55.274.
Stock Price History:
The Beta on a monthly basis for IMCR is 0.84, which has changed by -0.12238443 over the last 52 weeks, in comparison to a change of 0.11730647 over the same period for the S&P500. Over the past 52 weeks, IMCR has reached a high of $43.12, while it has fallen to a 52-week low of $23.15. The 50-Day Moving Average of the stock is 18.23%, while the 200-Day Moving Average is calculated to be 15.63%.
Shares Statistics:
IMCR traded an average of 402.07K shares per day over the past three months and 701460 shares per day over the past ten days. A total of 50.18M shares are outstanding, with a floating share count of 48.62M. Insiders hold about 3.12% of the company’s shares, while institutions hold 91.54% stake in the company. Shares short for IMCR as of 1747267200 were 7951194 with a Short Ratio of 19.78, compared to 1744675200 on 7681100. Therefore, it implies a Short% of Shares Outstanding of 7951194 and a Short% of Float of 21.83.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Immunocore Holdings plc ADR (IMCR) is currently shaped by the ongoing analysis conducted by 11.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.07 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$0.09 and -$1.87 for the fiscal current year, implying an average EPS of -$0.66. EPS for the following year is -$1.41, with 13.0 analysts recommending between -$0.1 and -$3.09.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 12 analysts. It ranges from a high estimate of $97.34M to a low estimate of $90.2M. As of the current estimate, Immunocore Holdings plc ADR’s year-ago sales were $75.4MFor the next quarter, 12 analysts are estimating revenue of $95.26M. There is a high estimate of $101.08M for the next quarter, whereas the lowest estimate is $91.11M.
A total of 14 analysts have provided revenue estimates for IMCR’s current fiscal year. The highest revenue estimate was $394.15M, while the lowest revenue estimate was $367.11M, resulting in an average revenue estimate of $378.26M. In the same quarter a year ago, actual revenue was $310.2MBased on 15 analysts’ estimates, the company’s revenue will be $406.52M in the next fiscal year. The high estimate is $458.52M and the low estimate is $370.63M.
